Publications

Categories
Search
Preclinical
May 16, 2024
PEGS
TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 costimulation, engineered to improve T cell function and antitumor responses in hard-to-treat cancers
Newhook et al.
Preclinical
April 17, 2024
Festival of Biologics
Next Generation Trispecific T Cell Engagers (TriTCE) Designed to Improve Treatment Responses in Oncology
Genevieve Desjardins
Preclinical
April 10, 2024
AACR
TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 co-stimulation, engineered to improve responses in the treatment of solid tumors
Newhook et al.
Preclinical
April 10, 2024
AACR
DLL3 TriTCE Co-Stim: A next generation trispecific T cell engager with integrated CD28 co-stimulation for the treatment of DLL3-expressing cancers
Repenning et al.
Preclinical
April 8, 2024
AACR
Development of three-dimensional cancer cell line spheroid models for the in vitro functional characterization of cytotoxic antibody-drug conjugates
Wong et al.
Preclinical
April 8, 2024
AACR
Screening novel format antibodies to design bispecific ADCs that address target heterogeneity
Barnscher et al.
Preclinical
April 8, 2024
AACR
ZW191 – a FRα-targeting antibody-drug conjugate with strong preclinical activity across multiple FRα-expressing indications
Lawn et al.
Preclinical
February 14, 2024
Molecular Cancer Therapeutics
Design and evaluation of ZD06519, a novel camptothecin payload for antibody drug conjugates
Petersen et al.
Preclinical
January 17, 2024
PepTalk
Engineering a Pure and Stable Heterodimeric IgA for the Development of Multispecific Therapeutics
Meghan Verstraete
Preclinical
November 4, 2023
SITC
TriTCE Co-Stim: A novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the therapeutic window for treatment of poorly infiltrated tumors
Newhook et al.
Preclinical
November 4, 2023
SITC
TriTCE CPI: a novel trispecific T cell engager platform with integrated PD-1/PD-L1 checkpoint inhibition engineered for the treatment of immunosuppressed tumors
Verstraete et al.
Zanidatamab
October 23, 2023
ESMO
Zanidatamab (ZW25), a HER2-Targeted Bispecific Antibody, in Combination With Chemotherapy and Tislelizumab in Patients With Advanced HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma: Updated Results From a Phase 1b/2 Study
Keun-Wook Lee, et al.